Intelligent Bio Solutions Inc Stock Price, News & Analysis

Intelligent Bio Solutions (Nasdaq: INBS) has expanded its non-invasive drug testing portfolio with the addition of the SmarTest® Patch, a wearable device developed by SMARTOX®. The innovative patch enables continuous drug detection through sweat over 7-10 days and can detect substances including cocaine, opiates, methamphetamines, marijuana, and fentanyl.

The water-resistant and tamper-evident patch complements INBS's flagship Intelligent Fingerprinting Drug Testing Solution, offering customers flexibility in detection timeframes while maintaining a non-invasive approach. The product expansion particularly targets justice and rehabilitation settings outside the U.S., strengthening the company's position in the non-invasive testing market.

Intelligent Bio Solutions (Nasdaq: INBS) announced it will present Pharmacokinetic (PK) study data at the ADLM 2025 Clinical Lab Expo in Chicago from July 27-31. The study demonstrates that their Intelligent Fingerprinting Drug Screening System effectively detects codeine through fingerprint sweat analysis, with results closely matching blood-based testing at a 95% confidence level.

The company's non-invasive drug screening technology is currently used across 450 accounts in 24 countries, serving various sectors including construction, transportation, and manufacturing. The presentation will be delivered by Daniel Brown, Head of Clinical Affairs, in the ADLM Poster Hall, featuring over 700 presentations.

Intelligent Bio Solutions (Nasdaq: INBS) reported successful expansion of its fingerprint drug testing technology across Scandinavia through its partnership with Spjotgard. The company's Drug Screening System, which delivers results in under 10 minutes using fingerprint sweat, has gained traction across 450 accounts in 24 countries.

The technology is being adopted across various sectors including logistics, construction, warehousing, education, and criminal justice. Spjotgard, founded in 2021, has established a strong presence in Sweden, Norway, and Denmark, with growing interest in Finland. The system offers advantages over traditional drug testing methods, providing a non-invasive, hygienic, and efficient solution for workplace safety and education sectors.

Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a major Australian waste management provider, will implement INBS' Intelligent Fingerprinting Drug Screening System across 20+ New South Wales operations sites. The system enables rapid, non-invasive drug testing through fingerprint sweat analysis in under 10 minutes, allowing MWS to conduct pre-employment, random, and for-cause testing on-site. This marks MWS's first implementation of in-house drug testing across multiple locations. The technology provides a portable, scalable solution that aligns with fieldwork requirements, eliminating the need for outsourced testing models. INBS' fingerprint drug testing technology is currently used by over 450 organizations across 24 countries.

Intelligent Bio Solutions (NASDAQ: INBS) reports significant progress in the U.S. Forensic Market through its partnership with SMARTOX. The Texas-based drug screening company has deployed over 50 Intelligent Fingerprinting Drug Screening Readers and conducted more than 7,000 tests, with 1,500+ completed in 2024. The fingerprint-based drug screening technology provides non-invasive, rapid results in under 10 minutes. INBS is actively pursuing FDA clearance for its opiate test system for codeine to expand into broader U.S. markets, including workplace drug testing. SMARTOX serves various forensic settings including corrections, drug courts, and rehabilitation centers, with an international presence across Europe, Latin America, New Zealand, and Australia.

Intelligent Bio Solutions (NASDAQ: INBS) announced its participation at RISE25, the leading U.S. conference on addiction, mental health, and justice innovation, taking place in Kissimmee, Florida from May 28-31, 2025. INBS will showcase its Intelligent Fingerprinting Drug Testing Solution alongside U.S. distribution partner SMARTOX.

The company's innovative system uses fingerprint sweat to detect recent use of cannabis, cocaine, methamphetamine, and opiates, delivering results in under 10 minutes. Currently used in the U.S. for Forensic Use Only, INBS is pursuing FDA approval to enter the broader U.S. market this year. The company maintains over 450 active accounts across 24 countries, demonstrating strong global demand for its drug testing solutions.

Intelligent Bio Solutions (NASDAQ: INBS) successfully completed a large-scale workforce drug testing operation at Barcaldine Regional Council in remote Queensland, Australia, using its Intelligent Fingerprinting Drug Screening System. The company tested 160 employees in under 90 minutes, demonstrating significant efficiency compared to traditional testing methods.

The fingerprint-based system delivered rapid results in under 10 minutes per test, allowing the entire workforce to be cleared for duty before 8:00 a.m. The Council has now been trained for in-house random testing, with plans for continued workforce testing through INBS's on-site model. The company currently serves over 450 accounts across 24 countries, marking this successful deployment as a strategic expansion into regional and remote workforce testing markets.

Intelligent Bio Solutions (NASDAQ: INBS) reported significant growth in its global fingerprint drug testing operations. The company has surpassed 450 active accounts across 24 countries, adding 35 new accounts in fiscal Q3. INBS's Intelligent Fingerprinting Drug Screening System, which delivers results in under 10 minutes through sweat analysis, has expanded into multiple sectors including manufacturing, transport, logistics, engineering, and mining.

Key expansion milestones include entry into Europe's luxury marine sector, regional testing programs in Australia, adoption in Australia's waste and recycling sector, and penetration into Australian retail. The company's distributor network now spans 19 countries through 18 partners. INBS is also planning to introduce a collected testing service and preparing for entry into the U.S. market.

Intelligent Bio Solutions (NASDAQ: INBS) reported strong fiscal Q3 2025 results, with 20% sequential quarterly revenue growth to $0.73 million and 91% year-over-year quarterly gross profit growth to $341,368. The company's high-margin cartridge sales now represent 58% of total revenue for the nine months ended March 31, 2025. INBS expanded its customer base by 35 new accounts, bringing total active accounts to over 450. The company enhanced its global presence through partnerships in Spain, Andorra, Europe, and the Middle East, while securing its sixth U.S. patent for the Intelligent Fingerprinting Drug Screening Cartridge. Financial highlights include total cash of $2.81 million, shareholders equity of $4.94 million, and a reduced net loss of $2.54 million. The company also launched multilingual functionality and expanded marketing initiatives across key regions.